Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model

Basit Öğe Kaydı
dc.contributor.authorOzansoy, Mehmet
dc.contributor.authorOzansoy, Muzaffer Beyza
dc.contributor.authorYuluğ, Burak
dc.contributor.authorÇankaya,Şeyda
dc.contributor.authorKılıç, Ertuğrul
dc.contributor.authorGöktekin, Şule
dc.contributor.authorKılıç, Ülkan
dc.date.accessioned2021-02-19T21:20:47Z
dc.date.available2021-02-19T21:20:47Z
dc.date.issued2020
dc.departmentALKÜ
dc.description.abstractBackground: Recent studies have been revealed that oxidative damage is the main cause of aging and age-related neurodegenerative diseases like Alzheimer's disease (AD). Melatonin is secreted from the pineal gland and its secretion has been found to be altered in AD. In the last decade the role of exosomes in spreading toxic proteins and inducing the propagation of diseases like AD has been discussed. However, it is not known how melatonin affects the amount of exosomes released from the cells and the content of the exosomes. Objective: Herein, we investigated the possible role of melatonin treatment in the releasing of exosomes and exosomal tau content in an in vitro A? toxicity model. Method: SH-SY5Y cell line was used. The optimum concentration of A? was determined by cell viability and cell proliferation tests. Melatonin (100 µM) was applied before and after A? application. Total exosomes isolated from cell culture media were immunoprecipitated. The amount of released exosomes and their tau content were analyzed by Western blots. Results: Our data demonstrated for the first time that melatonin treatment clearly affected the amount of released exosomes. It would decrease the amyloid beta load and toxicity by inhibiting exosome release. We also demonstated that melatonin also affected the level of tau carried by exosomes depending on whether melatonin was applied before or after A? application. Conclusion: It is considered that the effect of melatonin in the release of exosomes and exosomal tau content would contribute the development of therapeutic strategies in AD and related disorders. © 2019 Elsevier Ltd
dc.identifier.doi10.1016/j.jocn.2019.11.046
dc.identifier.endpage244en_US
dc.identifier.issn0967-5868
dc.identifier.pmid32061493
dc.identifier.scopusqualityQ1
dc.identifier.startpage237en_US
dc.identifier.urihttps://doi.org/10.1016/j.jocn.2019.11.046
dc.identifier.urihttps://hdl.handle.net/20.500.12868/688
dc.identifier.volume73en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor0-belirlenecek
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.ispartofJournal of Clinical Neuroscience
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAlzheimer's disease
dc.subjectAmyloid-beta
dc.subjectExosome
dc.subjectMelatonin
dc.subjectSH-SY5Y
dc.subjectTau
dc.titleMelatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu